Feasibility and oncologic outcomes of minimally invasive surgery after induction chemoimmunotherapy for non–small cell lung cancer

This is the authors' abstract. We don't add key points for this paper.

Objective: We evaluated the feasibility and long-term outcomes of minimally invasive surgery (MIS) after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer (NSCLC). Methods: Patients with stage IB-IIIB NSCLC who underwent induction immunotherapy followed by surgery (2015-2022) were included. Overall and event-free survival were estimated using the Kaplan-Meier approach. Cox regression was used to quantify associations between clinical and pathologic variables and survival outcomes. Conclusions: MIS after induction immunotherapy is feasible and does not compromise long-term oncologic outcomes.